TrialBritish journal of haematology2022

A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.

Paolo Strati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.